CRON Quote, Financials, Valuation and Earnings

Edesa Biotech has a net margin of 24.37% compared to Cronos Group's net margin of --. Cronos Group's return on equity of -4.33% beat Edesa Biotech's return on equity of --.

Cronos Group has a consensus price target of --, signalling upside risk potential of 0.03%. On the other hand Edesa Biotech has an analysts' consensus of $20.50 which suggests that it could grow by 1071.43%. Given that Edesa Biotech has higher upside potential than Cronos Group, analysts believe Edesa Biotech is more attractive than Cronos Group.

Cronos Group has a beta of 0.991, which suggesting that the stock is 0.93299999999999% less volatile than S&P 500. In comparison Edesa Biotech has a beta of 0.772, suggesting its less volatile than the S&P 500 by 22.837%.

Cronos Group has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Edesa Biotech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cronos Group pays -- of its earnings as a dividend. Edesa Biotech pays out -- of its earnings as a dividend.

Cronos Group quarterly revenues are $34.3M, which are larger than Edesa Biotech quarterly revenues of --. Cronos Group's net income of $8.3M is higher than Edesa Biotech's net income of -$962.1K. Notably, Cronos Group's price-to-earnings ratio is -- while Edesa Biotech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cronos Group is 6.88x versus 17.02x for Edesa Biotech. Usually stocks with elevated PS ratios are considered overvalued.

Lexaria Bioscience has a net margin of 24.37% compared to Cronos Group's net margin of -2121.06%. Cronos Group's return on equity of -4.33% beat Lexaria Bioscience's return on equity of -93.31%.

Cronos Group has a consensus price target of --, signalling upside risk potential of 0.03%. On the other hand Lexaria Bioscience has an analysts' consensus of -- which suggests that it could grow by 352.49%. Given that Lexaria Bioscience has higher upside potential than Cronos Group, analysts believe Lexaria Bioscience is more attractive than Cronos Group.

Cronos Group has a beta of 0.991, which suggesting that the stock is 0.93299999999999% less volatile than S&P 500. In comparison Lexaria Bioscience has a beta of 1.062, suggesting its more volatile than the S&P 500 by 6.234%.

Cronos Group has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lexaria Bioscience offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cronos Group pays -- of its earnings as a dividend. Lexaria Bioscience pays out -- of its earnings as a dividend.

Cronos Group quarterly revenues are $34.3M, which are larger than Lexaria Bioscience quarterly revenues of $84K. Cronos Group's net income of $8.3M is higher than Lexaria Bioscience's net income of -$1.8M. Notably, Cronos Group's price-to-earnings ratio is -- while Lexaria Bioscience's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cronos Group is 6.88x versus 58.77x for Lexaria Bioscience. Usually stocks with elevated PS ratios are considered overvalued.

Tilray Brands has a net margin of 24.37% compared to Cronos Group's net margin of -13.81%. Cronos Group's return on equity of -4.33% beat Tilray Brands's return on equity of -7.24%.

Cronos Group has a consensus price target of --, signalling upside risk potential of 0.03%. On the other hand Tilray Brands has an analysts' consensus of $2.18 which suggests that it could grow by 54.39%. Given that Tilray Brands has higher upside potential than Cronos Group, analysts believe Tilray Brands is more attractive than Cronos Group.

Cronos Group has a beta of 0.991, which suggesting that the stock is 0.93299999999999% less volatile than S&P 500. In comparison Tilray Brands has a beta of 2.084, suggesting its more volatile than the S&P 500 by 108.36%.

Cronos Group has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Tilray Brands offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cronos Group pays -- of its earnings as a dividend. Tilray Brands pays out -- of its earnings as a dividend.

Cronos Group quarterly revenues are $34.3M, which are smaller than Tilray Brands quarterly revenues of $229.9M. Cronos Group's net income of $8.3M is higher than Tilray Brands's net income of -$31.7M. Notably, Cronos Group's price-to-earnings ratio is -- while Tilray Brands's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cronos Group is 6.88x versus 1.37x for Tilray Brands. Usually stocks with elevated PS ratios are considered overvalued.

Xenon Pharmaceuticals has a net margin of 24.37% compared to Cronos Group's net margin of --. Cronos Group's return on equity of -4.33% beat Xenon Pharmaceuticals's return on equity of --.

Cronos Group has a consensus price target of --, signalling upside risk potential of 0.03%. On the other hand Xenon Pharmaceuticals has an analysts' consensus of $57.67 which suggests that it could grow by 50.1%. Given that Xenon Pharmaceuticals has higher upside potential than Cronos Group, analysts believe Xenon Pharmaceuticals is more attractive than Cronos Group.

Cronos Group has a beta of 0.991, which suggesting that the stock is 0.93299999999999% less volatile than S&P 500. In comparison Xenon Pharmaceuticals has a beta of 1.189, suggesting its more volatile than the S&P 500 by 18.926%.

Cronos Group has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xenon Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cronos Group pays -- of its earnings as a dividend. Xenon Pharmaceuticals pays out -- of its earnings as a dividend.

Cronos Group quarterly revenues are $34.3M, which are larger than Xenon Pharmaceuticals quarterly revenues of --. Cronos Group's net income of $8.3M is higher than Xenon Pharmaceuticals's net income of -$62.8M. Notably, Cronos Group's price-to-earnings ratio is -- while Xenon Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cronos Group is 6.88x versus 221.08x for Xenon Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.